
GlaxoSmithKline Acknowledges Misrepresentation in Scientific Article
One employee is dismissed, another has resigned, and three others are put on administrative leave.
GlaxoSmithKline (GSK) issued a
“The integrity of our research is critical to our work and when these allegations came to light, we immediately contacted the journal to tell them that we were taking the charges seriously and would be investigating thoroughly,” said GSK in the statement. “Regretfully, our investigation has established that certain data in the paper were indeed misrepresented. We’ve shared our conclusion that the paper should be retracted and are in the process of asking all of the authors to sign a statement to that effect, according to Nature Medicine’s procedure.”
GSK says that one individual has been dismissed from GSK, a second has submitted his resignation, and three others have been placed on administrative leave, pending a final review. “We are committed to the highest ethical and scientific standards and regulators, physicians, and patients can have confidence in the research we carry out.” said GSK in its statement.
Reference
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.